Table 1 Summary of patient characteristics
Characteristic | Value | N (%) N = 119 |
|---|---|---|
Gender | Male | 51 (42.9) |
Female | 68 (57.1) | |
Age, years | Mean (SD) | 57.5 (9.41) |
Median | 59.0 | |
Range | 23 to 74 | |
ECOG performance status | 0 | 51 (42.9) |
1 | 68 (57.1) | |
Melanoma subtypes | Non-acral cutaneous | 22 (18.5) |
acral | 62 (52.1) | |
mucosal | 23 (19.3) | |
unknown primary | 12 (10.1) | |
Metastatic stage | M0 | 27 (22.7) |
M1 | 40 (33.6) | |
M1a | 10 (8.4) | |
M1b | 26 (21.9) | |
M1c | 12 (10.1) | |
unknown | 16 (13.4) | |
Clinical stage | II | 1 (0.8) |
III | 27 (22.7) | |
IV | 86 (72.3) | |
Unknown | 5 (4.2) | |
Type of prior therapy | Surgery | 101 (84.9) |
Radiotherapy | 11 (9.2) | |
Chemotherapy | 83 (69.7) | |
Target therapy | 18 (15.1) | |
Immunotherapy (IFN-α 2b, IL-2, oncolytic viruses, CIK, NKT, et al.) | 52 (43.7) | |
Biotherapy | 11 (9.2) | |
Others | 36 (30.3) | |
Prior lines of treatment for advanced disease | 1 | 76 (63.9) |
2 | 34 (28.6) | |
 ≥ 3 | 9 (7.6) | |
liver metastasis | YES | 15 (12.6) |
NO | 104 (87.4) | |
NRAS gene mutation | Positive | 9 (7.6) |
Negative | 1 (0.8) | |
Unknown | 109 (91.6) | |
BRAF gene mutation | Positive | 13 (10.9) |
Negative | 47 (39.5) | |
Unknown | 59 (49.6) | |
LDH level | Normal | 72 (60.5) |
Higher than upper limit of normal (ULN) | 47 (39.5) |